Crospovidone Va 64 25086-89-9

pients and active ingredients have very good compatibility. Solid drugs containing PVPP tablet disintegrants can use common tablet production techniques, including direct compression, It is easy to produce by spraying, drying and wet granulation. Compressibility and adhesion Crospovidone nf has excellent fluidity and plastic deformation, so they have excellent adhesion. This property gives good compressibility in spraying, drying, and wet granulation. Adding PVPP tablet disintegrant to the tablet, compared with commonly used starch, cellulose preparations and pectin compounds, the hardness and abrasion resistance of the tablet are not affected, and the capping of the tablet is not reduced. Crospovidone nf can also be effectively used as a tablet disintegrant in direct compression, without the use of lubricants or the addition of binders. Capillary activity and hydration capacity Research work has shown that PVPP as a tablet disintegrant has high capillary activity and hydration capacity, because of their large specific surface area (average 1.25 m2/g) and significant water absorption (high and rapid water absorption) , Up to 60% or more). Swelling and disintegration PVPP has high capillary activity, so it can quickly absorb water into the tablet. Because the internal pressure (swelling pressure) exceeds the strength of the tablet, the tablet disintegrates instantly. And because there are folded molecular chains between the crosslinks, when water or aqueous solution penetrates, they are stretched by sudden impact and forced to separate immediately. As a result of swelling, the net volume increases (approximately doubled in 5 minutes), so that tablets prepared with PVPP tablet disintegrants disintegrate immediately.

Send Inquiry

Product Introduction

Product Description

Crospovidone Va 64 (CAS 25086-89-9) is a crosslinked copolymer of vinylpyrrolidone and vinyl acetate in a 60:40 ratio. A pharmacopeial superdisintegrant meeting USP and Ph.Eur standards, it enables rapid tablet disintegration through capillary swelling. Its particle size distribution is such that 90% of particles are smaller than 100μm.

It shows excellent compatibility with both excipients and active ingredients. Solid dosage forms containing this PVPP disintegrant can be produced using common tablet manufacturing techniques, including direct compression, spray drying, and wet granulation.

In terms of compressibility and adhesion, crospovidone NF boasts strong flow properties and plastic deformation, giving it excellent adhesive qualities. This translates to good compressibility in processes like spray drying and wet granulation. When added to tablets, unlike commonly used starches, cellulose preparations, or pectin compounds, it doesn't compromise tablet hardness or abrasion resistance, nor does it increase capping. It also works effectively as a disintegrant in direct compression-no lubricants or additional binders are needed.

Research highlights its high capillary activity and hydration capacity, thanks to a large specific surface area (average 1.25 m²/g) and significant water absorption (high and rapid, reaching 60% or more).

Its strong capillary activity allows it to quickly draw water into tablets. The swelling pressure generated exceeds the tablet's strength, causing immediate disintegration. Folded molecular chains between crosslinks stretch rapidly when water or aqueous solutions penetrate, forcing separation. This swelling leads to a nearly doubled volume within 5 minutes, ensuring tablets with PVPP disintegrant break down instantly.

Functional Performance Data

Disintegration time

≤30 seconds (IR formulations, 5% w/w concentration)

Water absorption

≥5.0 ml/g (vs. 4.0 ml/g for standard crospovidone)

Compactibility

Friability reduction >40% vs. MCC blends

Flowability

Carr index 15-20 (free-flowing after lubrication)

Stability

No gel formation in wet granulation

Release Specifications

Parameter	Specification
CAS No	25086-89-9
Crosslinking Density	8–12% DVB-equivalent
Residual Monomers	≤0.1% NVP / ≤0.1% VAc (HPLC)
Swelling Capacity	550–650% (0.1N HCl, 10 min)
pH (10% slurry)	5.0–8.0
Loss on Drying	≤6.0% (105°C, 4h)

Processing Protocol

1.Direct Compression: Use 2–8% w/w (optimize via sieve analysis)

2.Wet Granulation: Pre-blend with API; max 60°C drying temp

3.Reactivity: Avoid alkaline binders (pH >9 causes hydrolysis)

4.Packaging: 20kg PE-lined drums (nitrogen purge; RH <40%)

Tableting Advantages

◥ ODT Optimization: Disintegration <30 sec without effervescence

◥ High-Dose Compatibility: Stable with APIs up to 70% drug load

◥ Binder Synergy: Reduces HPMC concentration by 30–50%

◥ PAT Compatibility: NIR-transparent for in-line monitoring

Failure Mode Prevention

⊙Capping Risk: Maintain compression force <15 kN

⊙Sticking: Blend with 1–2% colloidal SiO₂

⊙Dissolution Variability: Control ambient RH <55% during compression

Advantages to choose us:

1.We are the factory, so the price is relatively favorable and very competitive

2. We have sufficient stocks to meet various order requirements

3. Our quality is stable and there will be no uneven quality

4. Our products are diversified to meet the needs of different customers

5. When necessary, we can provide some technical support

Hot Tags: Crospovidone Va 64 25086-89-9, China Crospovidone Va 64 25086-89-9 manufacturers, suppliers, factory, , Pvp K30 Polymer, pvpk30, Crospovidone Category, Povidone K30 Powder

Crospovidone Vs Copovidone25249-54-1

Polyvinylpyrrolidone K 90 9003-39-8